Abstract library

172 results for "hepatic steatosis".
#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Beatriz Arruda Matheos de Lima
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors
Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#637 Prognostic Factors Affecting Outcome in Patients with Liver Resection of Neuroendocrine Hepatic Metastasis
Introduction: Neuroendocrine (NE) malignant neoplasms commonly metastasize to the liver, which can be the only site of metastatic disease. The clinical course of patients who undergo surgical resection of hepatic NE metastases varies widely and the reported factors affecting survival have not been identified.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Franco Lumachi
#686 Hepatic Arterial Embolization for Gastroenteropancreatic NET Liver Metastases
Introduction: Selective hepatic arterial embolization (HAE) with polyvinyl alcohol particles has been shown to be equivalent to chemoembolization for patients with hepatic gastroenteropancreatic (GEP) neuroendocrine metastases. There remains debate about its clinical effectiveness and which patients benefit from treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Mr Colin Wilson
#883 Primary Hepatic Neuroendocrine Tumors: Four Familial Case Series with Review of Literature
Introduction: Non-multiple endocrine neoplasia (MEN) familial neuroendocrine tumors (NET) are very rare with only six families being described to date. Primary hepatic neuroendocrine tumors (PHNETs) are rare tumors with a particular sporadic diagnosis. Herein, we report a series of four members of one Lebanese family, diagnosed with primary hepatic neuroendocrine tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Rita E Assi
#1061 Transcatheter Arterial Chemoembolization for Unresectable Metastatic Hepatic Lesions of Pancreatic Neuroendocrine Tumors
Introduction: The blood supply of metastatic hepatic neuroendocrine tumors is mainly supplied by hepatic arteries. For unresectable metastatic NETs, selective embolisation of the hepatic arteries may be therapeutic.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Bao Xin
Authors: Xin B, Lou W, Ji Y, Liu L X, ...
Keywords: pnet, hepatic lesion, tace
#1259 Expressions of ATRX and DAXX in Hepatic Metastatic Pancreatic Nonfunctional Neuroendocrine Neoplasms
Introduction: Loss of ATRX or DAXX is common in well-differentiated pancreatic neuroendocrine neoplasms, and is correlated with higher tumor stage and shorter survival time.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Bao Xin
Authors: Xin B, Lou W, Ji Y, Xie Y, ...
#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.
Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD Simona Glasberg
#822 Hepatic Metastases of Gastroenteropancreatic Neuroendocrine Tumors: A 17-Year Single Center Prospective Study
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) with hepatic metastases (HM) have a poorer prognosis in comparison with localized GEP NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Matilde P Spampatti